In Trastuzumab-Resistant Metastatic Breast Cancer, Small Molecule Inhibitor Shows Pro

[News]

Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy. "I think this is very promising.

More... (http://www.medicalnewstoday.com/articles/151895.php)